To Evalaute the Efficacy of Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes Mellitus Patients by Assesing the HBA1C Percentage Reduction as a Single Diagnostic Tool for Glycemic Control and its Incidence in Preventing Macrovascular Complications: A Prospective Open Label Study for a Period

Aim: To evaluate the efficacy of metformin monotherapy in newly diagnosed type 2 mellitus patients by assessing the hba1c reduction percentage and thereby preventing the incidence of macrovascular complications.

Materials and Method: A total of 50 type 2 diabetes mellitus patients were included in the study.and after obtaining the informed consent the patients were advised to take Tablet metformin 500mg twice daily and hba1c were done at baseline, 3 and 6 months of the study period and the patients were assessed periodically and if any adverse events were reported it was recorded and manged promptly.

Results: HBA1C baseline value expressed as Mean±SD was 7.966±0.85 %. After 3 months of metformin therapy, HBA1C mean obtained was 7.53±0.83 %. After 6 months of metformin therapy, HBA1C improved to 6.8±0.93. Treatment with Metformin showed effective reduction in HBA1C values comparatively between HBA1C baseline values and HBA1C values at sixth month were statistically significant(P<0.05).

Conclusion: From the above results the current study shows significant reduction in hba1c values after six months of metformin therapy and this proves that metformin is a sole antidiabetic agent started as monotherapy in newly diagnosed diabetic patients the incidence of macrovascular complications can be prevented at the intial stage of the disease.